Quote | Medicenna Therapeutics Corp. (TSXC:MDNA:CC)
Last: | $2.02 |
---|---|
Change Percent: | -3.81% |
Open: | $2.1 |
Close: | $2.10 |
High: | $2.1 |
Low: | $2 |
Volume: | 23,946 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Medicenna Therapeutics Corp. (TSXC:MDNA:CC)
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...
Message Board Posts | Medicenna Therapeutics Corp. (TSXC:MDNA:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Medicenna Therapeutics Corp. Company Name:
MDNA:CC Stock Symbol:
TSXC Market:
Medicenna Therapeutics Corp. Website:
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...
Lomiko Metals Inc. (LMR:CA) is expected to report for Q3 2024 Organto Foods Inc. (OGO:CA) is expected to report for Q1 2024 PreveCeutical Medical Inc. (PREV:CNX) is expected to report for Q1 2024 Blue Horizon Global Capital Corp Com (BHCC:CNX) is expected to report for Q1 2024 Per...